Colpitts Che C, Chung Raymond T, Baumert Thomas F
Inserm, U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, 3 Rue Koeberlé, 67000 Strasbourg, France.
Université de Strasbourg , 67000 Strasbourg, France.
ACS Infect Dis. 2017 Sep 8;3(9):620-623. doi: 10.1021/acsinfecdis.7b00091. Epub 2017 Aug 16.
Entry inhibitors are emerging as an attractive class of therapeutics for hepatitis C virus (HCV) infection. Entry inhibitors target either virion-associated factors or cellular factors necessary for infection. By blocking entry into cells, entry inhibitors prevent both the establishment of persistent reservoirs and the emergence of resistant variants during viral replication. Furthermore, entry inhibitors protect naïve cells from virus-induced alterations. Combining entry inhibitors with direct-acting antivirals (DAAs) may therefore improve treatment outcomes, particularly in the context of organ transplantation. The role of DAAs in transplantation, while still under clinical investigation, carries the risk of recipient infection and HCV-induced disease, since DAAs act only after infection is established. Thus, entry inhibitors provide a perspective to improve patient outcomes during organ transplantation. Applying this approach for transplant of organs from HCV-positive donors to HCV-negative recipients may also contribute to alleviate the medical burden of organ shortage.
进入抑制剂正成为治疗丙型肝炎病毒（HCV）感染的一类有吸引力的疗法。进入抑制剂靶向病毒体相关因子或感染所需的细胞因子。通过阻断进入细胞的过程，进入抑制剂可防止在病毒复制期间建立持续的病毒库以及耐药变异体的出现。此外，进入抑制剂可保护未感染的细胞免受病毒诱导的改变。因此，将进入抑制剂与直接作用抗病毒药物（DAA）联合使用可能会改善治疗效果，尤其是在器官移植的情况下。DAA在移植中的作用虽然仍在临床研究中，但存在受者感染和HCV诱导疾病的风险，因为DAA仅在感染确立后才起作用。因此，进入抑制剂为改善器官移植期间的患者预后提供了一个视角。将这种方法应用于将HCV阳性供体的器官移植给HCV阴性受者，也可能有助于减轻器官短缺的医疗负担。
